Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We have revised prior periods to conform to current year presentation:

	Three Months Ended March 31,
	2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	312	$	220	$	531	$	280	$	219	$	499
Urology and Pelvic Health	286		127		413		257		104		361
Neuromodulation	161		49		209		151		46		198
MedSurg	758		395		1,153		689		369		1,058
Interventional Cardiology Therapies	186		358		544		195		331		526
Watchman	203		23		226		149		22		170
Cardiac Rhythm Management	325		195		519		276		193		469
Electrophysiology	50		68		118		30		53		83
Cardiology	764		644		1,407		650		599		1,248
Peripheral Interventions	256		210		465		238		195		433
Cardiovascular	1,019		853		1,873		888		793		1,681
Specialty Pharmaceuticals	—		—		—		10		4		13
Total Net Sales	$	1,778	$	1,248	$	3,026	$	1,586	$	1,166	$	2,752

Refer to Note K- Segment Reporting for information on our reportable segments.

	Three Months Ended March 31,
Regions	2022		2021
U.S.	$	1,778	$	1,577
Europe, Middle East and Africa	624		604
Asia-Pacific	517		473
Latin America and Canada	107		85
Medical Devices	3,026		2,739
U.S.	—		10
International	—		4
Specialty Pharmaceuticals	—		13
Total Net Sales	$	3,026	$	2,752
Emerging Markets(1)	$	390	$	317

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently

includes the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam.